ALUR — ALLURION TECHNOLOGIES, INC.
—
OTC ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1964979 ·
Last close
$0.56
Market Cap
$8.48M
52W High
$1.22
52W Low
$0.37
ADV30
43,867
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,947,000 | 1,229,000 | -3,731,000 | -6,095,000 | 13,995,000 | 5,056,000 | 91,905,000 |
| Dec 2025 | 3,613,000 | 1,608,000 | -6,294,000 | -6,035,000 | 15,772,000 | 5,412,000 | 92,961,000 |
| Sep 2025 | 2,658,000 | 1,304,000 | -9,630,000 | -11,884,000 | 18,141,000 | 6,136,000 | 101,069,000 |
| Jun 2025 | 3,379,000 | 2,497,000 | -6,952,000 | -9,335,000 | 28,169,000 | 12,722,000 | 92,145,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,698,000
Investing CF
$0
Financing CF
$7,337,000
CapEx
$-72,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.07
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-257,057,000
Inventory
$2,061,000
Receivables
$3,475,000
ST Investments
—
EBIT TTM
$-31,528,000
Pretax Income TTM
$-33,348,000
Interest Exp TTM
$1,820,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$12,597,000
EBITDA
$-27,055,000
Free Cash Flow
$-13,369,750
Enterprise Value
$81,829,728
Total Cash
$5,056,000
Total Debt
$78,246,000
Shares Out
15,006,253
Trailing EPS
$-3.96
Book Value
$-5.20
ROE
—
ROA
-66.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 15,230,000 | -30,157,000 | -28,755,000 | 15,772,000 | 92,961,000 | — | -28,946,000 |
| Dec 2024 | 32,110,000 | -50,198,000 | -7,198,000 | 32,813,000 | 110,791,000 | — | -42,300,000 |
| Dec 2023 | 53,467,000 | -79,078,000 | -82,817,000 | 71,712,000 | 143,009,000 | — | -63,982,000 |
| Dec 2022 | 64,211,000 | -32,010,000 | -37,744,000 | 51,370,000 | 83,684,000 | — | -46,981,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NXL | Nexalin Technology, Inc. | $8.47M | $0.39 | — |
| VVOS | Vivos Therapeutics, Inc. | $7.57M | $0.54 | — |
| ALRTF | ALR Technologies SG Ltd. | $9.68M | $0.01 | — |
| STME | Stimcell Energetics Inc. | $7.36M | $0.35 | — |
| NVNO | enVVeno Medical Corp | $7.04M | $10.54 | — |
News headlines (Yahoo Finance, 1h cache)
Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum
2026-06-02 13:00 · Yahoo
Allurion Treats First Commercial Patients in the United States, Marking Major Milestone
2026-04-20 12:30 · Yahoo
Allurion Advances Plan to Regain Listing Compliance
2026-03-12 20:15 · Yahoo
Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy
2026-03-11 13:00 · Yahoo
Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE
2026-03-02 14:00 · Yahoo
Are Medical Stocks Lagging Allurion Technologies, Inc. (ALUR) This Year?
2026-02-27 14:40 · Yahoo
Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
2026-02-24 14:15 · Yahoo
Allurion Receives U.S. FDA Approval
2026-02-23 14:00 · Yahoo
Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
2026-02-03 14:00 · Yahoo
Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
2026-01-12 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.